Sage Therapeutics reported $6.2 million in ZURZUVAE collaboration revenue and $1.7 million in ZULRESSO revenue for the first quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $717 million as of March 31, 2024.
Achieved $6.2 million in ZURZUVAE collaboration revenue, representing 50% of Biogen's net revenues.
Over 700 ZURZUVAE prescriptions were shipped and delivered in Q1 2024.
Payor coverage is in place for a majority of commercially covered lives for ZURZUVAE in the treatment of women with postpartum depression (PPD).
Phase 2 PRECEDENT Study for dalzanemdor in Parkinson’s Disease did not meet the primary endpoint.
Sage anticipates that its existing cash, cash equivalents and marketable securities, anticipated funding from ongoing collaborations, and estimated revenues, will support its operations into 2026. The Company anticipates operating expenses will decrease in 2024 relative to 2023.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance